Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review

 

Rating

3.8 Star Rating for report Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review
3.8 / 5 stars rating
Pages: 69
Price: $125.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. 

Description

Biogen Inc (Biogen) is a global biotechnology company that discovers, develops, manufactures and commercializes therapies for treating neurodegenerative diseases, hematologic conditions and autoimmune disorders. The company's marketed product portfolio includes Avonex, Tysabri, Tecfidera, Fampyra, and Plegridy for the treatment of multiple sclerosis (MS); Eloctate for hemophilia A; Alprolix for hemophilia B and Fumaderm (fumaric acid esters) for plaque psoriasis. Through its joint venture company, Samsung Bioepis the company also develops, manufactures and markets biosimilars. The company also has several products in its developmental pipeline targeting various indications namely MS, hemophilia and other neurodegenerative diseases. The company markets its products in the US, several European countries and Japan through its own sales forces and marketing groups. Biogen is headquartered in Cambridge, Massachusetts, the US.

Biogen Inc Key Recent Developments

Aug 09, 2016: Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company
Jul 22, 2016: Medidata Cloud Technology Selected to Support Biogen Clinical Trials
Jul 21, 2016: Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion
Jun 28, 2016: Biogen Selects Cognizant's SmartTrials Platform
Jun 21, 2016: Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology
 

Similar Reports

Other reports that may be of interest...

Report... 05IC-GDPH1000046SAAlcami Corp - Strategic SWOT Analysis ReviewSep 2017
Report... 05IC-GDPH113806SAColorcon Inc - Strategic SWOT Analysis ReviewJan 2017
Report... 05IC-GDPH223733SAChildren's Medical Center - Strategic SWOT Analysis ReviewNov 2017
Report... 05IC-GDPH5315FSAGilead Sciences Inc (GILD) - Financial and Strategic SWOT Analys...Apr 2017
Report... 05IC-GDPH66490FSALa Jolla Pharmaceutical Company (LJPC) - Financial and Strategic...Aug 2017
Report... 05IC-GDPH4235FSABioDelivery Sciences International Inc (BDSI) - Financial and St...May 2017
Report... 05IC-GDPH7218FSAMyriad Genetics Inc (MYGN) - Financial and Strategic SWOT Analys...Oct 2017
Report... 05IC-GDPH81714FSAArray BioPharma Inc (ARRY) - Financial and Strategic SWOT Analys...Sep 2017
Report... 05IC-GDPH82505FSAOrexigen Therapeutics Inc (OREX) - Financial and Strategic SWOT ...Apr 2017
Report... 05IC-GDPH224942SAArkansas Children's Hospital - Strategic SWOT Analysis ReviewOct 2017

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-08-17 

Report: Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review

 

Contents

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Biogen Inc - Key Facts 6
Biogen Inc - Key Employees 7
Biogen Inc - Key Employee Biographies 8
Biogen Inc - Major Products and Services 10
Biogen Inc - Pharmaceutical Pipeline Products Data 12
Biogen Inc, Pipeline Products by Therapy Area 12
Biogen Inc, Pipeline Products by Development Phase 13
Biogen Inc - History 17
Biogen Inc - Company Statement 27
Biogen Inc - Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Joint Venture 33
Section 2 - Company Analysis 34
Biogen Inc - Business Description 34
Biogen Inc - Corporate Strategy 36
Biogen Inc - SWOT Analysis 37
SWOT Analysis - Overview 37
Biogen Inc - Strengths 37
Strength - Focus on Multiple Sclerosis Market 37
Strength - Focused Research and Development Activities 37
Strength - Operational Network 37
Biogen Inc - Weaknesses 38
Weakness - Clinical Discontinuations 38
Weakness - Product Recalls - Tecfidera 38
Weakness - Decline in Revenue from Avonex 38
Biogen Inc - Opportunities 39
Opportunity - Market Potential - Multiple Sclerosis 39
Opportunity - Inorganic Growth Strategies 39
Opportunity - Business Initiatives 39
Biogen Inc - Threats 40
Threat - Competitive Pressures 40
Threat - Stringent Government Regulations 40
Threat - Legal Proceedings 40
Biogen Inc - Key Competitors 41
Section 3 - Company Financial Ratios 42
Financial Ratios - Capital Market Ratios 42
Financial Ratios - Annual Ratios 43
Performance Chart 45
Financial Performance 45
Financial Ratios - Interim Ratios 46
Financial Ratios - Ratio Charts 47
Section 4 - Company's Lifesciences Financial Deals and Alliances 48
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 48
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 49
Biogen Inc, Recent Deals Summary 50
Section 5 - Company's Recent Developments 51
Aug 09, 2016: Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company 51
Jul 22, 2016: Medidata Cloud Technology Selected to Support Biogen Clinical Trials 52
Jul 21, 2016: Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion 53
Jun 28, 2016: Biogen Selects Cognizant's SmartTrials Platform 56
Jun 21, 2016: Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology 57
Jun 21, 2016: BMS and Biogen to Give Biomanufacturing Keynote Presentations at CHI's Eighth Annual The Bioprocessing Summit 58
May 03, 2016: Biogen Announces Intent to Spin off Its Hemophilia Business 59
Apr 29, 2016: Adam Koppel, Executive Vice President, Strategy And Business Development, To Return To Bain Capital 61
Apr 27, 2016: Biogen Appoints Michael Ehlers Executive Vice President, Research and Development 62
Apr 21, 2016: Biogen Reports First Quarter 2016 Revenues of $2.7 Billion 63
Section 6 - Appendix 65
Methodology 65
Ratio Definitions 65
About GlobalData 69
Contact Us 69
Disclaimer 69
 

List of Tables

List of Tables
Biogen Inc, Key Facts 6
Biogen Inc, Key Employees 7
Biogen Inc, Key Employee Biographies 8
Biogen Inc, Major Products and Services 10
Biogen Inc, Number of Pipeline Products by Therapy Area 12
Biogen Inc, Number of Pipeline Products by Development Stage 13
Biogen Inc, Pipeline Products By Therapy Area and Development Phase 14
Biogen Inc, History 17
Biogen Inc, Other Locations 28
Biogen Inc, Subsidiaries 28
Biogen Inc, Joint Venture 33
Biogen Inc, Key Competitors 41
Biogen Inc, Ratios based on current share price 42
Biogen Inc, Annual Ratios 43
Biogen Inc, Interim Ratios 46
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 48
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 49
Biogen Inc, Recent Deals Summary 50
Currency Codes 65
Capital Market Ratios 65
Equity Ratios 66
Profitability Ratios 66
Cost Ratios 67
Liquidity Ratios 67
Leverage Ratios 68
Efficiency Ratios 68
 

List of Figures

List of Figures
Biogen Inc, Pipeline Products by Therapy Area 12
Biogen Inc, Pipeline Products by Development Phase 13
Biogen Inc, Performance Chart (2011 - 2015) 45
Biogen Inc, Ratio Charts 47
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 48
Biogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 49
 

Scope

The profile contains critical company information including:

- Business description - A detailed description of the company's operations and business divisions.
- Corporate strategy - Analyst's summarization of the company's business strategy.
- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities - A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

 

Classification

Language Code: EN 
Region: United States 
Report Type: Company Reports 
Industry: Life Sciences 
Sector: Life Sciences 
Pages: 69 

Companies Featured

Teva Pharmaceutical Industries Ltd. Synthetic Biologics, Inc. Sanofi Receptos, Inc. Pfizer Inc. Pfenex Inc. Opexa Therapeutics, Inc. Novartis AG Merck & Co., Inc. MediciNova, Inc. Johnson & Johnson Genzyme Corporation Genmab Ltd. Forward Pharma A/S BG Medicine, Inc. Bayer HealthCare Pharmaceuticals Active Biotech AB AbbVie Inc

 

Reasons to buy this report

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
 

Similar Reports

Other reports that may be of interest...

Report... 05IC-GDPH1000046SAAlcami Corp - Strategic SWOT Analysis ReviewSep 2017
Report... 05IC-GDPH113806SAColorcon Inc - Strategic SWOT Analysis ReviewJan 2017
Report... 05IC-GDPH223733SAChildren's Medical Center - Strategic SWOT Analysis ReviewNov 2017
Report... 05IC-GDPH5315FSAGilead Sciences Inc (GILD) - Financial and Strategic SWOT Analys...Apr 2017
Report... 05IC-GDPH66490FSALa Jolla Pharmaceutical Company (LJPC) - Financial and Strategic...Aug 2017
Report... 05IC-GDPH4235FSABioDelivery Sciences International Inc (BDSI) - Financial and St...May 2017
Report... 05IC-GDPH7218FSAMyriad Genetics Inc (MYGN) - Financial and Strategic SWOT Analys...Oct 2017
Report... 05IC-GDPH81714FSAArray BioPharma Inc (ARRY) - Financial and Strategic SWOT Analys...Sep 2017
Report... 05IC-GDPH82505FSAOrexigen Therapeutics Inc (OREX) - Financial and Strategic SWOT ...Apr 2017
Report... 05IC-GDPH224942SAArkansas Children's Hospital - Strategic SWOT Analysis ReviewOct 2017

Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review

Report 01B4-GDPH1307FSA has a rating of 75 percent
Figure of merit assessment for report 01B4-GDPH1307FSA

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1555

Taxonomy Location

The taxonomy on the left shows the ancestors of the United States node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

United States

The US has the largest economy in the world. It is highly industrialised and some of the main industries include; petroleum, steel, motor vehicles, aerospace, telecommunications, chemicals, electronics, food processing, consumer goods, lumber and mining.  

The US economy is dealing with slow growth rates, unemployment and increasing national debt since the recession of 2008/2009 however economists expect much higher growth in the US economy in 2014. The IMF expects growth to increase from 1.9% in 2013 to 2.8% in 2014.  The IMF expects a drop in unemployment to 6% in 2014. The indicators are good. The private sector is growing, federal spending will continue and some of the underlying drags on the economy are diminishing. Cheaper energy coming from increased oil exploration, gas fracking and renewables has helped to bring more jobs back to the US. The manufacturing sector is growing again and manufacturing technology is improving. 

There is a shortage of housing as a result of limited construction in recent years. Satisfying this demand should provide a much needed boost for the construction industry. There has also been considerable under investment in many other areas of the economy during the credit crunch and it is expected that there will be growth in the IT sector as companies carry out much needed upgrading of systems. 

Inequality is a major issue in the US economy. More of the wealth is going to the top 1% of high earners and middle incomes are stagnant. Tax reform is necessary for the redistribution of wealth. By putting more money in the pockets of the lower and middle classes the US economy will start to see some real growth.

Researchandexperts.com is a leading source of market research on key industry sectors in the USA.

Useful Links

World Bank Overview of the United States

CIA World Factbook on the United States

The International Monetary Fund on the US Economy

United States

Northern America

Region

 

North America

The term North America usually refers to the US and Canada sometimes including Geenland, Mexico and the islands of Bermuda, St Helena and Saint Pierre et Miquelon.  

North America is dominated by the largest global economy, the United States. The main industries in the US are technology, petroleum, steel, motor vehicles, aerospace, telecommunications, chemicals, electronics, food processing, consumer goods, lumber and mining. The US main tading partners are Canada, China, Mexico, Japan, and Germany. Canada is one of the largest economies in the world and is listed as one of the G8. Canada has a well established services sector along with well established industries in the areas of maufacturing, mining and logging. Canada's main trading partners are US, EU, China and Mexico.

 Research and Experts, the market intelligence platform, provides companies with access to the latest leading industry reports covering the North American region. Our company reports contain the following information; company overviews, key facts, key employees, products and services, as well as financial ratios. Our industry reports are vital sources of detailed historic and forecast values for markets in North America, segmented at category level.

Research and Experts reports also provide regional analysis and analysis of the leading companies in key North American markets.  Researchandexperts.com is a  leading source of market research on North America.

North America

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 205

Taxonomy Location

The taxonomy on the left shows the ancestors of the Life Sciences node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review

 

Item Code: 01B4-GDPH1307FSA

 
Licence: Single User
Price: $125.00
 
VAT: 0.0% 
Total: $125.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [1.45242s]

--